Charlotte Ezratty

ORCID: 0000-0002-8724-3640
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Multiple and Secondary Primary Cancers
  • Advanced Breast Cancer Therapies
  • BRCA gene mutations in cancer
  • Cancer Treatment and Pharmacology
  • Dementia and Cognitive Impairment Research
  • Peripheral Artery Disease Management
  • Neuroendocrine Tumor Research Advances
  • Breast Cancer Treatment Studies
  • Cerebrovascular and Carotid Artery Diseases
  • Ovarian cancer diagnosis and treatment
  • Menopause: Health Impacts and Treatments
  • Childhood Cancer Survivors' Quality of Life
  • Cancer-related cognitive impairment studies
  • Coronary Interventions and Diagnostics
  • Breast Lesions and Carcinomas
  • Reproductive Biology and Fertility
  • Digital Radiography and Breast Imaging
  • Estrogen and related hormone effects
  • Neuroblastoma Research and Treatments
  • Health Systems, Economic Evaluations, Quality of Life
  • Cancer survivorship and care
  • Global Cancer Incidence and Screening

Icahn School of Medicine at Mount Sinai
2020-2024

Previvors are becoming more aware of the option risk-reducing salpingectomy with delayed oophorectomy (RRS-DO) to mitigate their risk ovarian cancer. In this qualitative study, we explored clinical and non-clinical factors that impacted previvors' decision-making pursue RRS-DO as a reduction strategy.Semi-structured telephone interviews were conducted previvors transcribed verbatim. Using ATLAS.ti® software, two primary investigators interpreted data through thematic analysis. After coding...

10.1016/j.gore.2022.100948 article EN cc-by-nc-nd Gynecologic Oncology Reports 2022-02-26

e13098 Background: Aromatase inhibitors (AIs) are the most used adjuvant treatment in post-menopausal women with favorable oncotype, hormone receptor-positive (HR+) early breast cancer. Nonsteroidal AIs, such as anastrozole and letrozole, associated menopausal side effects including arthralgias, vaginal dryness, hot flashes. Steroidal exemestane, however, have mild androgenic activity, thus minimizing risk for these effects. While studies show exemestane exhibits less bone toxicity compared...

10.1200/jco.2024.42.16_suppl.e13098 article EN Journal of Clinical Oncology 2024-06-01

Cognitive impairment (CI) is highly prevalent in breast cancer survivors (BCS), and can be a barrier to health-promoting behaviours. However, the ways which CI may affect self-regulation or motivation perform such behaviours have not been explored. We assessed if BCS with report greater extrinsic compared those without this relationship persists after controlling for depression.We recruited diabetes cognition healthy management (e.g., diet exercise). Participants completed cognitive battery...

10.1002/pon.5633 article EN Psycho-Oncology 2021-01-23

Abstract Introduction: Advances in breast cancer (BC) diagnosis and treatment have increased the number of long-term survivors. Consequently, survivors primary BC are at a greater risk developing second cancers (SPCs). The factors for SPCs among including sociodemographic, treatment, comorbidities, other medications not been comprehensively examined. purpose this study is to assess incidence clinicopathologic associated with SPCs. Methods: We analyzed 170, 639 women early-stage diagnosed...

10.21203/rs.3.rs-1028396/v1 preprint EN cc-by Research Square (Research Square) 2021-11-09

e22542 Background: Genetic testing plays an important role in the detection and management of breast cancer. Patients with high-risk mutations may undergo more frequent screening possible risk reduction medical surgical management. also guides treatment decisions, including recent approval adjuvant olaparib for patients BRCA1/2-mutated early-stage The most NCCN guidelines expand age recommendation genetic a personal history cancer from ≤ 45 years to 50 though clinical practice, it is likely...

10.1200/jco.2023.41.16_suppl.e22542 article EN Journal of Clinical Oncology 2023-06-01

Abstract Introduction : Advances in breast cancer (BC) diagnosis and treatment have increased the number of long-term survivors. Consequently, primary BC survivors are at a greater risk developing second cancers (SPCs). The factors for SPCs among including sociodemographic characteristics, treatment, comorbidities, concurrent medications not been comprehensively examined. purpose this study is to assess incidence clinicopathologic associated with Methods We analyzed 171, 311 women...

10.21203/rs.3.rs-1028396/v2 preprint EN cc-by Research Square (Research Square) 2022-05-25
Coming Soon ...